Trials / Terminated
TerminatedNCT05565092
Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease
A Phase 2a, Randomized, Open-Label Study to Evaluate Multiple Dosing Regimens of Subcutaneous ALXN1820 in Adult Participants With Sickle Cell Disease
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the safety and tolerability of ALXN1820 SC (subcutaneous) in participants with SCD (Sickle Cell Disease).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALXN1820 | ALXN1820 will be administered subcutaneously. |
Timeline
- Start date
- 2023-02-22
- Primary completion
- 2024-01-09
- Completion
- 2024-01-09
- First posted
- 2022-10-04
- Last updated
- 2025-01-13
- Results posted
- 2025-01-13
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05565092. Inclusion in this directory is not an endorsement.